AZAFAROS B.V.

📍 Naarden, Netherlands🗓 Founded 2018👥 22 employees💰 Last funded May 2025
Biotechnology Research🌐 azafaros.com
Website LinkedIn
We are developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound, nizubaglustat, will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program in the clinic while further expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Italy
1
Frequently asked questions
Who invested in AZAFAROS B.V.?
AZAFAROS B.V. has 1 investors on record on gritt.io and 1 late-stage investors.
When did AZAFAROS B.V. last raise funding?
The most recent investment in AZAFAROS B.V. recorded on gritt.io was in May 2025.
When was AZAFAROS B.V. founded?
AZAFAROS B.V. was founded in 2018.
What industry is AZAFAROS B.V. in?
AZAFAROS B.V. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AZAFAROS B.V. based?
AZAFAROS B.V. is headquartered in Naarden, Netherlands.